Literature DB >> 23123689

Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease.

Santiago Perez-Lloret1, María Verónica Rey, Nelly Fabre, Fabienne Ory, Umberto Spampinato, Christine Brefel-Courbon, Jean-Louis Montastruc, Olivier Rascol.   

Abstract

BACKGROUND: Impulse-control disorders (ICDs) occur in patients with Parkinson disease (PD), especially in younger patients on dopamine therapies.
OBJECTIVE: To assess the prevalence of ICD symptoms and its pharmacological correlations in a sample of French patients with PD and without PD (poststroke).
METHODS: Outpatients with PD and without PD (poststroke) were screened for compulsive behaviors related to hypersexuality, compulsive shopping, pathological gambling, or compulsive eating by means of the Questionnaire for Impulse-Control Disorders--short version. Full medical history and Unified Parkinson's Disease Rating Scale scores were also recorded. Dose of dopamine agonists were converted to defined daily doses (DDDs), according to the World Health Organization Anatomical Therapeutic Chemical classification system classification system.
RESULTS: Two hundred three patients with PD and 52 patients without PD were recruited (mean ± SD age, 67 ± 1 vs 69 ± 2, P= 0.4; males: 62% vs 55% P= 0.2). Symptoms of ICDs were reported by 0% of poststroke patients and 25% of the patients with PD (P < 0.001). Hypersexuality was reported by 10% of the patients with PD, compulsive shopping by 6%, pathological gambling by 3%, and compulsive eating by 14%. A logistic regression analysis found that age younger than 68 years (odds ratio [OR], 3.3; 95% confidence interval, 1.6-6.6) and exposure to dopamine agonists (OR, 20.3; 95% confidence interval, 2.7-65.0) or monoaminooxidase-B inhibitor (OR, 3.7; 95% confidence interval, 1.1-12.6) were significant factors associated with increased ICD frequency. Patients with ICD symptoms were exposed to higher dopamine doses than those without them (1.6 ± 0.1 vs 1.0 ± 0.1 daily-defined doses; P < 0.001). A dose-response pharmacodynamic model disclosed a significant nonlinear dose-response relationship between dopamine agonists and frequency of ICD symptoms (P < 0.01).
CONCLUSIONS: Impulse-control disorder symptoms were more frequent in the patients with PD than in the poststroke patients with PD. Impulse-control disorder symptoms were related to younger age and exposure to monoaminooxidase-B inhibitors, and showed a nonlinear dose-response relationship with dopamine agonists.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23123689     DOI: 10.1097/WNF.0b013e31826e6e6d

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  24 in total

1.  Clozapine use for refractory impulse control disorders in Parkinson's disease: a case report.

Authors:  Nicolas A Bonfils; Amine Benyamina; Henri-Jean Aubin; Amandine Luquiens
Journal:  Psychopharmacology (Berl)       Date:  2015-08-21       Impact factor: 4.530

2.  Factors to Consider in the Selection of Dopamine Agonists for Older Persons with Parkinson's Disease.

Authors:  Mark Dominic Latt; Simon Lewis; Olfat Zekry; Victor S C Fung
Journal:  Drugs Aging       Date:  2019-03       Impact factor: 3.923

Review 3.  New pharmacological and neuromodulation approaches for impulsive-compulsive behaviors in Parkinson's disease.

Authors:  Giacomo Grassi; Giovanni Albani; Federica Terenzi; Lorenzo Razzolini; Silvia Ramat
Journal:  Neurol Sci       Date:  2021-04-14       Impact factor: 3.307

4.  Longitudinal analysis of impulse control disorders in Parkinson disease.

Authors:  Jean-Christophe Corvol; Fanny Artaud; Florence Cormier-Dequaire; Olivier Rascol; Franck Durif; Pascal Derkinderen; Ana-Raquel Marques; Frédéric Bourdain; Jean-Philippe Brandel; Fernando Pico; Lucette Lacomblez; Cecilia Bonnet; Christine Brefel-Courbon; Fabienne Ory-Magne; David Grabli; Stephan Klebe; Graziella Mangone; Hana You; Valérie Mesnage; Pei-Chen Lee; Alexis Brice; Marie Vidailhet; Alexis Elbaz
Journal:  Neurology       Date:  2018-06-20       Impact factor: 9.910

Review 5.  Amantadine Revisited: A Contender for Initial Treatment in Parkinson's Disease?

Authors:  Sarah Marmol; Matthew Feldman; Carlos Singer; Jason Margolesky
Journal:  CNS Drugs       Date:  2021-10-14       Impact factor: 5.749

Review 6.  Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.

Authors:  Barbara Connolly; Susan H Fox
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 7.  Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease.

Authors:  Santiago Perez-Lloret; Olivier Rascol
Journal:  CNS Drugs       Date:  2016-08       Impact factor: 5.749

Review 8.  Treatment of advanced Parkinson's disease.

Authors:  Juan C Giugni; Michael S Okun
Journal:  Curr Opin Neurol       Date:  2014-08       Impact factor: 5.710

Review 9.  Does the Country Make a Difference in Impulse Control Disorders? A Systematic Review.

Authors:  Paloma Parra-Díaz; Juan Luis Chico-García; Álvaro Beltrán-Corbellini; Fernando Rodríguez-Jorge; Clara Lastras Fernández-Escandón; Araceli Alonso-Cánovas; Juan Carlos Martínez-Castrillo
Journal:  Mov Disord Clin Pract       Date:  2020-12-21

10.  Diagnosis and treatment of impulse control disorders in patients with movement disorders.

Authors:  Tiago A Mestre; Antonio P Strafella; Teri Thomsen; Valerie Voon; Janis Miyasaki
Journal:  Ther Adv Neurol Disord       Date:  2013-05       Impact factor: 6.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.